UNSPSC 51123401: Cibenzoline

This classification denotes an anti-arrhythmia agent with the molecular formula C18H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Z7489237QT, chemically known as 1h-imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)- but more generally known as cibenzoline, which bears US NIH Compound Identifier 2747. European Medicines Agency schedules Cibenzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06229MIG.

UNSPSC 51123401 Cibenzoline is a Commodity code covering individual pharmaceutical products procured by state and local governments for emergency medical services, institutional pharmacy programs, and cooperative purchasing alliances. The code sees application in emergency life support medication procurement, multi-state generic pharmaceutical contracting, and direct-to-manufacturer pharmacy benefit initiatives. State and local buying bodies soliciting under this code include municipal fire-rescue services, state health and human services departments, and multi-state cooperative purchasing consortia. The work involves supplying regulated pharmaceutical products with strict expiration-date and shelf-life requirements, compliance with cGMP and Drug Supply Chain Security Act standards, and delivery into authorized wholesaler networks or direct emergency services procurement channels. Vendors must carry comprehensive liability insurance, maintain Safety Data Sheets compliant with OSHA standards, and provide detailed product information including National Drug Codes, packaging configurations, and manufacturing locations.

Recent activity appears concentrated in Florida and Minnesota, with emerging exploration in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation includes a 5 percent SLBE bid discount not to exceed $10,000. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness on July 1, 2026; evaluation weighs price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with response due April 3, 2026, to inform future formal procurement strategy.